Style | Citing Format |
---|---|
MLA | Tajali R, et al.. "Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α." Advanced Pharmaceutical Bulletin, vol. 13, no. 2, 2023, pp. 350-360. |
APA | Tajali R, Eidi A, Tafti HA, Pazouki A, Sharifi AM (2023). Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α. Advanced Pharmaceutical Bulletin, 13(2), 350-360. |
Chicago | Tajali R, Eidi A, Tafti HA, Pazouki A, Sharifi AM. "Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α." Advanced Pharmaceutical Bulletin 13, no. 2 (2023): 350-360. |
Harvard | Tajali R et al. (2023) 'Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α', Advanced Pharmaceutical Bulletin, 13(2), pp. 350-360. |
Vancouver | Tajali R, Eidi A, Tafti HA, Pazouki A, Sharifi AM. Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α. Advanced Pharmaceutical Bulletin. 2023;13(2):350-360. |
BibTex | @article{ author = {Tajali R and Eidi A and Tafti HA and Pazouki A and Sharifi AM}, title = {Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α}, journal = {Advanced Pharmaceutical Bulletin}, volume = {13}, number = {2}, pages = {350-360}, year = {2023} } |
RIS | TY - JOUR AU - Tajali R AU - Eidi A AU - Tafti HA AU - Pazouki A AU - Sharifi AM TI - Restoring the Angiogenic Capacity of the Human Diabetic Adipose-Derived Mesenchymal Stem Cells Primed With Deferoxamine As a Hypoxia Mimetic Agent: Role of Hif-1Α JO - Advanced Pharmaceutical Bulletin VL - 13 IS - 2 SP - 350 EP - 360 PY - 2023 ER - |